At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- DNA Analysis (other)
- How long the study runs
- Study runs about 71 months (dates as stated)
- About the drug or intervention
- DNA Analysis — other: Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies \& subsequent resections
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 19 Years and over
- Who
- All
- Number of participants
- 20
- Started
- 2020-11-18
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for head and neck cancer
- • Clinical study - 20 participants
- • Radical radiotherapy for head and neck squamous cell cancer (HNSCC) can be administered to primary disease with curative intent
Who can take part?
- • Ages 19 Years and over
- • Diagnosed with head and neck cancer
Where?
- • London - The Royal Marsden Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Radical radiotherapy for head and neck squamous cell cancer (HNSCC) can be administered to primary disease with curative intent. Residual disease, recurrence or further tumours may subsequently occur in this irradiated field. It is unknown whether these cancers reflect primary resistance or represent the evolution of resistance on treatment. Understanding this could allow stratification of patients to more effective primary treatments, such as transoral robotic surgery, or help tailor systemic therapies for these cancers in previously irradiated fields. RECUT+ is an exploratory molecular analysis study to assess the selective impact of radiation therapy on HNSCC. Participants will be recruited from the Royal Marsden Hospital (RMH), Chelsea, a tertiary referral H\&N cancer unit in London, UK, specialising in transoral robotic surgery. Retrospective participants will be identified from previous Head and neck MDT lists at RMH. Prospective participants will be screened for by the RECUT+ team during the weekly H\&N MDT meetings at the Royal Marsden Hospital (RMH). Blood/saliva samples will be collected pre operatively (prospective participants) and post operatively (retrospective and prospective participants) for germline and circulating tumour DNA analysis. Biopsy samples from the original cancer and resected specimens from the post radiotherapy residual/recurrent/new primary disease will undergo molecular analysis to assess for any selective impact of radiotherapy on these further tumours.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 19 Years and over
- Who can join: All genders
What the study is looking for
- ✓Inclusion criteria
- ✓Aged over 18
- ✓Previous H\&N cancer treated with radiotherapy.
- ✓Undergoing TORS as part of their management for residual, recurrent or new primary H\&N cancer.
- ✓Exclusion criteria
See the full criteria
Where Is This Study? (1 UK site)
The Royal Marsden Hospital
London SW3 6JJ, United Kingdom
How to Get in Touch
Vishak C Muraleedharan Shylaja, MBChB
Sponsor contactCONTACT
Sarah Burton
Sponsor contactCONTACT